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Abstract
Introduction: With the improvement of therapeutic options for the treatment of breast cancer, the development
of brain metastases has become a major limitation to life expectancy in many patients. Therefore, our aim was to
identify molecular markers associated with the development of brain metastases in breast cancer.
Methods: Patterns of chromosomal aberrations in primary breast tumors and brain metastases were compared
with array-comparative genetic hybridization (CGH). The most significant region was further characterized in more
detail by microsatellite and gene-expression analysis, and finally, the possible target gene was screened for
mutations.
Results: The array CGH results showed that brain metastases, in general, display similar chromosomal aberrations
as do primary tumors, but with a notably higher frequency. Statistically significant differences were found at nine
different chromosomal loci, with a gain and amplification of EGFR (7p11.2) and a loss of 10q22.3-qter being among
the most significant aberrations in brain metastases (P < 0.01; false discovery rate (fdr) < 0.04). Allelic imbalance (AI)
patterns at 10q were further verified in 77 unmatched primary tumors and 21 brain metastases. AI at PTEN loci was
found significantly more often in brain metastases (52%) and primary tumors with a brain relapse (59%) compared
with primary tumors from patients without relapse (18%; P = 0.003) or relapse other than brain tumors (12%; P =
0.006). Loss of PTEN was especially frequent in HER2-negative brain metastases (64%). Furthermore, PTEN mRNA
expression was significantly downregulated in brain metastases compared with primary tumors, and PTEN
mutations were frequently found in brain metastases.
Conclusions: These results demonstrate that brain metastases often show very complex genomic-aberration
patterns, suggesting a potential role of PTEN and EGFR in brain metastasis formation.
Introduction
Breast cancer is the most common malignancy in
women, with the mortality rate being especially high in
patients in whom brain metastases develop. Approxi-
mately 15% to 20% of breast cancers metastasize to the
brain, although incidence rates are increasing [1]. The
incidence of metastases is thought to be increasing
because of the improved treatment of metastases at
other distant sites and advances in imaging techniques,
leading to improved detection of central nervous system
(CNS) metastases [2].
Metastasis formation is a highly selective, multistep
process, involving complex interactions between tumor
and host cells. To metastasize, tumor cells must disen-
gage from the primary tumor, invade the stroma, and
penetrate into vessels, where they disseminate, extrava-
sate, and start to grow at distant organ sites. As a distant
metastatic site, the brain forms a special challenge for
tumor cells because of the blood-brain barrier [3]. In
addition, all other steps have to be successfully completed
for the tumor cell to survive and expand. The molecular
basis for all of these steps is still unclear, and several
models have been suggested [4,5].
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Comparative gene-expression analyses on primary
breast tumors and lymph node metastases have indicated
that, in general, metastases have very similar expression
signatures compared with their parent tumors [6,7].
However, detailed analyses have also revealed that a
number of genes are consistently differentially expressed
between primary tumors and metastases [8-10] and that
metastases often show a greater variety of aberrations
than the primary tumor [11,12]. At the chromosomal
level, even greater differences have been described
between primary breast tumors and their derived metas-
tases. Most of the relevant studies compared the chromo-
somal aberrations in matched primary breast tumors and
lymph node metastases [13-16], and only a very few stu-
dies on distant metastases exist [17-19]. In general, all of
these studies showed that metastases harbor more and
also new aberrations that could not be found in the cor-
responding primary tumors (reviewed in [20]). These
results imply that the clonal evolution of a tumor is more
complex than would be predicted by linear models, high-
lighting the importance of investigating distant metas-
tases as the end point of the metastatic cascade.
In this study, the patterns of chromosomal aberrations
of primary tumors and brain metastases from breast can-
cer patients were compared with array-comparative geno-
mic hybridization (CGH) and microsatellite analysis. The
goal was to identify genetic alterations in the primary
breast tumors associated with metastatic spread to the
brain to be able to define subgroups of high-risk breast
cancer patients. Our results indicate that loss of 10q and
especially phosphatase and tensin homologue (PTEN)
could be predictive factors for the development of brain
metastases. Interestingly, whereas loss of PTEN is gener-
ally very rarely seen in most epithelial tumors, it is one of
the most frequent aberrations found in primary glioblasto-
mas [21] and other CNS malignancies [22,23], indicating
that loss of PTEN might be an important factor for breast
tumor cell survival in the CNS environment.
Materials and methods
Patient collection
All samples were collected from female patients who
underwent surgical resection at the University Medical
Center, Hamburg-Eppendorf, Germany. For array CGH
profiling, unmatched fresh-frozen tumor samples were
collected from 30 primary breast cancer patients, with 10
breast cancer samples that had metastasized to the brain.
All primary tumors were of an early stage, and none
relapsed to the brain at a later stage (mean follow-up of
58.8 months). The mean age of the patients at brain
metastases surgery was 57 years, with an average of 11
years (range, 4 to 30 years) between primary tumor diag-
nosis and brain relapse (Additional file 1).
For allelic-imbalance (AI) analysis, 77 primary breast
tumor (55 fresh-frozen and 22 paraffin-embedded sam-
ples) and 21 brain metastases (all fresh-frozen) samples
were analyzed. To avoid misleading results by analyzing
unmatched samples, the primary tumor samples were
matched for the main clinicopathologic characteristics in
the AI analysis. Ten of the primary tumors later showed a
relapse to the brain, and 17, to other sites. Eighteen of the
primary tumor cases and eight metastases overlapped with
the array samples, and five pairs of primary and corre-
sponding metastases were available (Additional file 1).
Four pairs of matched primary tumor and brain metas-
tases were also available.
This study was approved by the Ethics Committee of
the Chamber of Physicians, Hamburg, Germany, and
sample donors gave written informed consent.
HER2 status
The HER2 status was first assessed in both the primary
tumors and the brain metastases with immunohistochem-
ical tests (Dako HercepTest; Dako, Glostrup, Denmark)
according to the manufacturer’s instructions. All cases
with an immunoscore of 3+ were considered to be HER2
positive, whereas all cases with a score of 2+ were reevalu-
ated with fluorescence in situ hybridization (FISH) (Path-
Vysion Kit Vysis; Abbott, Abbott Park, IL, USA). Tumor
tissue in which the HER2-FISH signal to centromere 17
ratio was > 2 was also considered HER2 positive.
Array CGH
Genomic DNA was isolated (QIAmpDNA MicroKit; Qia-
gen, Hilden, Germany) from fresh cryosections for the
array CGH analysis and part of the microsatellite analysis.
If necessary, manual microdissection was performed to
obtain a tumor-cell content of at least 70% [24]. Total
volumes of 300 ng of tumor DNA and 300 ng of reference
DNA (pooled leukocyte DNA of 10 healthy men) were
labeled with Cy3- and Cy5-labeled dCTP, respectively, and
co-hybridized on 30 K oligonucleotide CGH microarrays.
The array contains 60 mer oligonucleotides representing
28,830 unique genes designed by Compugen (Human
Release 2.0 oligonucleotide library; San Jose, CA, USA)
[25]. The raw signal intensities were obtained by using
Agilent’s Feature Extraction software program after bad-
quality spots were removed by using BlueFuse Version 3.1
(BlueGenome, Cambridge, UK). We used a sex-mismatch
in the hybridization (that is, DNA of the opposite gender
was used as a reference). Subsequently, the X and Y chro-
mosomes were excluded for downstream data analysis.
The log2 ratios were centered to a median of zero, and the
resulting log2 ratio values for each probe were segmented
by using GLAD in R [26]. All probes within the genomic
bounds of a given GLAD-derived segment were given the
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mean copy-number value of the probes within that seg-
ment. Copy-number values > 0.05 log2 ratio units repre-
sented a gain and values < -0.05 log2 ratio units
represented a loss. The cut-off points were based on the
variance found in the X and Y reference chromosomes.
After segmentation, the log2 ratios were centered to a
median of zero by using only normal segments, and the
segmentation was repeated. All CGH data are available at
ArrayExpress [27].
Microsatellite analysis
Microsatellite analysis was carried out to verify the loss of
10q and to reveal the extent of the aberration in 77 pri-
mary and 21 brain metastases. Tumor DNA was isolated
in 22 cases from paraffin-embedded samples, also using
macrodissection to achieve a minimum of 70% tumor cells
in the samples. The DNA was extracted by using the Innu-
PREP DNA Microkit (AnalytikJena, Jena, Germany). For
reference DNA, DNA samples isolated from peripheral
blood mononuclear cells or nonmalignant normal breast
tissue were used. Allelic imbalance in the chromosomal
region 10q22.3-qter (chr10:80,522,854-134,299,490; 53.8
MBp) was first assessed by using eight microsatellite mar-
kers with an approximate spacing of 10 MBp. Three addi-
tional microsatellite markers were analyzed in samples
that contained enough DNA and showed a partial AI
(Additional file 2). The FAM or HEX end-labeled poly-
merase chain reaction (PCR) products were analyzed with
a Genetic Analyzer 3130 (Applied Biosystems, Darmstadt,
Germany). GeneScan software (Applied Biosystems) was
used to study the lengths of the allele fragments and fluor-
escence intensity. The allelic imbalance (AI) was deter-
mined for heterozygous markers by calculating the ratio of
the peak heights of the tumor and normal alleles. Ratios of
2.0 or higher were scored as AI.
PTEN mutation analysis
For the 10 brain metastases samples, the entire PTEN cod-
ing region was screened for mutations by sequencing
PTEN cDNA. For an additional 10 samples, exons 3 and 5
were sequenced for mutations (Additional file 2). For the
sequencing of cDNA total RNA was extracted from fresh-
frozen tissue by using the Qiagen Minikit (Qiagen, Hilden,
Germany), and then the total RNA was reverse transcribed
by using a First Strand cDNA Synthesis Kit (Fermentas, St.
Leon-Rot, Germany). First, the complete coding region
was amplified, followed by sequencing PCR for both DNA
strands. When multiple PCR products were detected, the
respective bands were gel-purified by using the GelExtract
Mini Kit (5Prime, Hamburg, Germany), and 40 ng of the
purified product was used for the sequencing PCR by
using the BigDye Terminator v1.1 Cycle Sequencing Kit
(Applied Biosystems, Freiburg, Germany). For genomic
DNA, PCRs were performed by using exon-spanning
primer pairs for exons 3 and 5, as described in Danielsen
et al. [28]. The PCR products were purified by using the
PCRExtract Mini Kit (5Prime), and subsequent sequencing
PCR was performed by using 30 ng of DNA. The
sequences were determined in a Genetic Analyzer 3130
(Applied Biosystems).
Gene-expression analysis of the 10q gene in primary
tumors and brain metastases
Array data from the 32 untreated primary breast tumors
without relapse included in GEO DataSet [GSE21974]
(including 10 basal-like and 22 non-basal-like tumors)
and nine brain metastases samples (the same samples as
used for CGH analysis, except for one sample from
which no RNA could be extracted) were compared for
differentially expressed genes. The datasets, which both
were analyzed on the Agilent Whole Human Genome
Microarray 4 × 44K, were combined, quantile normal-
ized, and checked for systematic differences between the
two array groups. Subsequently, differentially expressed
genes were selected by using the significance analysis of
microarrays (SAM) algorithm with a false-discovery rate
(fdr) of 5%. To narrow the results, in a second step, only
transcripts with an expression level at the 25th percentile
or greater of the overall expression level, located on chro-
mosome 10 with a fold change (FC) > 2, were taken into
account.
In addition, a data set from Zhang et al. [11] GEO Data-
Set [GSE14020] was analyzed to see whether a difference
in the PTEN expression exists among different primary
tumor patients with different relapse patterns. The data
set consist of primary breast tumors with 22 cases of brain
relapse, 20 cases with lung relapse, and 18 cases with bone
relapse. The CEL files were processed by using GCRMA.
Differentially expressed genes (brain versus bone relapse
and brain versus lung relapse) were identified by repeated
permutation testing with the SAM algorithm by using a
5% fdr.
Statistical analysis
Statistical analyses were performed within the R statistical
environment. For array CGH data, differences between
primary tumors and brain metastases with respect to
copy-number changes were determined per probe region
by using CGHMultiarray, which is based on the Wilcoxon
rank-sum test and is implemented in the CGHtest R-pack-
age [29,30]. Raw P values were corrected for multiple test-
ing by using Benjamini and Hochberg’s False Discovery
Rate method [31].
The relation between microsatellite markers and clini-
cal factors was examined by means of the c2 test and of
independence. Differences between primary tumors and
brain metastases in relation to allelic imbalance were
calculated with the Fisher Exact test.
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Results
Comparative analysis of primary and metastatic breast
tumors with array CGH
To identify chromosomal aberrations that function as
molecular markers for brain metastasis, array CGH
screening was performed on both primary breast tumors
and brain metastases. Copy-number changes were found
in all samples (n = 40) and on each chromosome arm. The
most frequently observed gains (> 30% of cases) in the pri-
mary tumors were found at 1q, 8q, 16p, 17, and 20, and
the most common losses were at 1p, 8p, 11q, 13, 16q, 17p,
and 22 (Figure 1a). In the brain metastases, a high degree
of aberration was found on almost every chromosome,
with the most common gains (> 30% of cases) at 1q, 5p, 7,
8q, 10p, 11p, 12p, 15q, 18, 20, and 22, and losses at 3p, 8p,
9p, 10q, 11, 12p, 13, 15, 17, and 18q (Figure 1b).
The results showed a very similar pattern of genetic aber-
rations in both primary and metastatic breast tumors (that
is, the metastases carried the majority of genetic alterations
present in the corresponding primary tumors but with a
significantly higher frequency). Whereas 20 loci were
gained or amplified and 17 lost in brain metastases (with >
30% difference), only gains of 1p and 16p and a loss of 16q
were most frequently found in the primary tumors.
After correction for multiple testing (fdr < 0.04), nine
regions were found to differ significantly (P < 0.05)
between the primary tumors and metastases (Table 1).
The most striking difference between the primary tumors
and metastases was found at chromosome 10q, showing a
loss of 10qter in 60% to 90% of the metastases, whereas
only none to 13% of the primary tumors harbored a loss
(P < 0.002). The terminal arm of chromosome 10p was
often gained in the metastases (40%) compared with pri-
mary tumors, where no such gain was found (none) (P =
0.005). Gains of 7p22.2-p15.3 and 7p11.2 (EGFR) were
found in 70% to 80% of the metastases but in only 10% to
13% of the primary tumors (P = 0.001 to 0.003, respec-
tively). Interestingly, deletion at chromosome 17 in the
primary tumors involved only the p-arm, whereas in brain
metastases, most of the q-arm also was involved, except
for the HER2 locus.
Twenty loci in the primary tumors showed a high-level
amplification, whereas in the brain metastases, 10 loci har-
bored a high-level amplification. In general, no significant
difference could be found in the number and distribution
of high-level amplifications between the primary and
metastatic tumors. The most common high-level amplifi-
cation was the HER2 amplification at 17q21, which was
found in 6% of primary and 20% of metastatic tumors
(Additional file 3).
Microsatellite analysis at 10q
Microsatellite analyses for allelic imbalances (AIs) were
carried out to verify the CGH results and to assess the
extent of loss on 10q. Between eight and 11 microsatel-
lite markers spanning a 54-MBp region on 10q were
used to screen a total of 21 brain metastasis and 77 pri-
mary tumor samples, including four matched pairs of
primary tumors and metastases (Figure 2). The primary
tumor cohort was matched for the main clinicopatholo-
gic characteristics.
Significant differences in AI frequencies were found
between the brain metastases and primary tumors with-
out relapse (P = 0.05) (Table 2): 62% of brain metastases
and 38% of the primary breast tumors were found to be
carriers of AI in the 10q region. Interestingly, samples
from primary tumors without a history of subsequent
brain relapse or from patients with a relapse to organs
other than the brain (28% and 18%, respectively) showed
fewer AI than did primary tumors from patients with
relapse to the brain (50%).
The frequency of AI for individual markers varied
between 18% and 43% in the primary tumors and 37%
and 50% in the brain metastases. Interestingly, the AI
did not cover the entire region but was concentrated
around two core regions (Additional file 4). The first
core region (CR1) was found around the PTEN locus
(markers D10S541 and D10S1765), and the second
region (CR2) was detected around markers D10S173
and D10S190. In particular, the AI in the CR1 (around
the PTEN) locus was observed significantly more often
in brain metastases than in primary tumors from
patients without later relapse (P = 0.003) or relapse to
organs (P = 0.006) other than the brain (Table 2).
Furthermore, AI around the PTEN locus (CR1) was
more common in HER2-negative brain metastases
(seven of 11; 64%) compared with HER2-positive brain
metastases (three of nine; 33%). The HER2 status was
not inversely associated with AI at the PTEN locus in
the primary tumors (19% and 25% in HER2-negative
and HER2-positive primary tumors, respectively) (Fig-
ure 2).
The size of AI was often quite small (sometimes cov-
ering only one microsatellite marker) in many of the
primary tumors, which could explain its rare detection
by CGH. In general, however, allelic-imbalance detec-
tion was in good accordance with the results indicated
by the CGH array (Figure 2).
Matched primary-tumor and brain-metastasis samples
were available for AI analysis in four cases. Three cases
showed identical aberration patterns at 10q, one normal
and two AI, whereas in the fourth case, the AI was lar-
ger (that is, in the metastases, the distal marker was also
affected by AI (Figure 2)).
In the primary tumors, AI at any locus was not signifi-
cantly associated with any clinical or histopathologic
factors (including hormone-receptor and HER2 status)
other than brain relapse (Additional file 5).
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Differentially expressed genes at 10q loci
In in silico gene-expression analysis, we identified 49
transcripts residing in 10q22.3-qter that were signifi-
cantly downregulated in the brain metastases samples
compared with unmatched primary breast tumors with-
out relapse. The first 6.3 MBp-large AI core region
around markers D10S541 and D10S1765 (PTEN/CR1)
contained nine different transcripts that were signifi-
cantly downregulated. The tumor-suppressor gene PTEN
was among these mostly uncharacterized genes. The sec-
ond 6.4-MBp-large AI hot spot around the markers
D10S173 and D10S190 (CR2) contained eight different
transcripts, including the recently described tumor-sup-
pressor gene HTRA1 [32] and three other genes (GFRA1,
HSPA12A, RGS10) known to be involved in brain-related
diseases (Additional file 6) [33-35].
To see whether a difference exists in PTEN expression
patterns among different primary tumor patients with dif-
ferent relapse patterns, the GSE14020 data set was ana-
lyzed. SAM analysis revealed a significant downregulation
of PTEN expression in patients with brain relapse com-
pared with patients with bone relapse (Additional file 7).
Figure 1 Frequency plot of the CGH results. In primary (a) breast tumors and brain metastases (b), The positive Y axis shows the percentage
of patient samples with gains, and the negative Y axis shows the percentage of patient samples with losses. Chromosomes are ordered from 1
to 22 on the X axis. Chromosomal borders are marked with solid vertical lines, and centromere positions, with dotted lines.
Wikman et al. Breast Cancer Research 2012, 14:R49
http://breast-cancer-research.com/content/14/2/R49
Page 5 of 11
Interestingly, the PTEN expression was not significantly
different between patients with lung or brain relapse (data
not shown).
PTEN mutation screening in brain metastases
The entire coding region in 10 brain-metastasis samples
was sequenced for PTEN mutations. In addition, 10 sam-
ples were used to sequence exons 3 and 5 for mutations.
Table 3 shows the three tumor samples (15%) with muta-
tions. Two patients were carriers of a splice-site muta-
tion. In one tumor, the cDNA lacked a complete exon 4.
In the second tumor, both alleles were mutated, resulting
in one product with a deletion of exons 4 to 6 and the
second product with a complex translocation and dupli-
cation of exon 3. The deletion of exon 4 in the cDNA
was shown to be caused by a 41-bp deletion in the intron
3-exon 4 junction of PTEN. Because of the complex nat-
ure of the translocations and deletions of both alleles in
the second case, no clear sequencing product on genomic
DNA could be obtained. The third mutation was
detected in exon 5 (c.389G > T). This base-pair substitu-
tion causes an amino acid change of arginine to lysine (p.
R130L) in the active-site pocket of the phosphatase
domain, which is essential for catalysis [36]. This muta-
tion was previously described as causing a loss of PTEN
protein expression [37].
Discussion
Central nervous system metastases are a frequent compli-
cation of many solid tumors. Approximately 15% of all
epithelial tumors metastasize to the brain, with incidence
rates highly dependent on the primary tumor type.
Whereas prostate cancer very rarely metastasizes to the
brain (1% to 5%), small-cell lung cancer (40%) and breast
cancer (15% to 20%) commonly metastasize to the brain
[38]. Apparently, the brain microenvironment is espe-
cially permissive for the growth of disseminated tumor
cells from some carcinomas but not from others. The
mechanisms by which metastatic tumor cells adapt to the
selection pressure exerted by the brain microenviron-
ment are still unknown.
In this study, our aim was to identify putative molecular
markers associated with the development of brain metas-
tases in breast cancer. First, we screened for chromosomal
aberrations by array CGH. The most prominent finding of
the loss of 10q in brain metastases was validated in a lar-
ger study population, and the tumor-suppressor gene
PTEN was found to be the potential target gene in this
region.
Overall, the array CGH results of the primary breast
tumors were in agreement with those described pre-
viously [39-41]. In general, the brain metastases showed
aberration patterns similar to those of the primary
tumors. However, in the brain metastases, a remarkably
higher frequency of gains and losses was found at almost
every chromosomal locus. Only a gain at 1p and a loss at
16q, described as being typical of luminal breast tumors
and as markers of a favorable prognosis, were more com-
mon in the primary tumors [39-41]. This finding is not
surprising, as most of the primary tumors were hormone
receptor (HR) positive, whereas 38% of the brain metas-
tases were HR negative. Statistically significant differ-
ences were found between the primary breast tumors
and brain metastases at nine different loci on six different
chromosomes.
The most significant differences were found at chromo-
somes 7 and 10. Chromosome 7 contains two regions,
7p22-p15 and 7p11.2, that were gained or amplified in
more than 70% of the metastases and gained in only 3%
to 13% of the primary tumors. Whereas the 22-Mbp
region 7p22.1-p15.3 contains many genes, the second
gained region on chromosome 7 contains only one gene,
the epidermal growth factor receptor (EGFR); EGFR is a
well-known and important gene in breast cancer initia-
tion and progression [42]. Recently, Gaedcke et al. [43]
reported a de novo protein expression of EGFR in the
brain metastases of matched primary and metastatic
breast cancer cases, and mouse models have shown the
Table 1 Statistically significantly different regions between primary breast tumors and brain metastases
Chrom. regiona bp start bp end Size (Mbp) % del PT % gain PT % del MET % gain MET P value Fdr
1 p22.1-21.2 94472000 101828000 7.4 25.8 3.2 0.0 20.0 0.005 0.04
7 p22.1-15.2 5383000 27787000 22.4 3.2-12.9 12.9 0.0 70.0-80.0 0.001-0.002 0.01-0.02
p11.2 54565000 55475001 0.5 0.0 9.7-12.9 0.0 70.0 0.001-0.003 0.01-0.02
10 pter-p12.1 173000 28895000 28.7 0.0 0.0 20.0 40.0 0.005 0.04
q11.22-q21.1 49685000 59935000 10.3 3.2 6.5 60.0 20.0 0.005 0.04
q22.1-qter 71226000 134848000 63.6 0-12.9 3.2-6.5 60.0-90.0 0.0-10.0 0.001-0.002 0.02
11 pter-p15.4 188000 9693000 9.5 12.9-19.4 9.7-12.9 70.0 0.0 0.001-0.005 0.01-0.04
16 q24.2 87416000 87465000 0.0 87.1 0.0 30.0 0.0 0.002 0.02
17 q11.2 26591000 29500000 2.9 16.1-22.6 25.8-29.0 70.0 0.0 0.001-0.005 0.01-0.04
fdr, false discovery rate; MET, brain metastasis; PT, primary tumor. aThe complete region that was statistically significantly different between the two groups
(primary versus metastasis). Therefore, some break points in some patients might occur within the region, causing a variation in the frequencies of deletions/
amplifications within a region and P values and fdr.
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EGFR ligand HBEGF to be one of the key mediators of
cancer-cell passage through the blood-brain barrier [5].
Most of the long arm of chromosome 10 was lost in
60% to 90% of the brain metastases, but only in none to
13% of the primary tumors. Numerous previously pub-
lished large-array CGH datasets, also including locally
advanced breast cancer, seldom showed a loss of 10q
[39-41]. The loss of 10q is, in general, rarely seen in
most epithelial tumors, whereas it is the most common
aberration found in glioblastomas, and it also is com-
mon in other CNS malignancies [21,22]. Similarly, the
gain of 7p is among the most frequently found gains in
astrocytomas [44]. Both aberrations also are present in
melanomas, which often metastasize to the brain
Figure 2 Microsatellite analyses for AI on 10q in primary breast cancers and metastases. Base-pair position and the markers used are
indicated on the top line. The result for each marker is shown as follows: AI, black; noninformative, light gray; unavailable measurement, dark
gray; and informative without changes, white box. 1, 2, 3, 4, matching primary tumors and brain metastases; a: loss from bp:100000000; b: loss
from bp: 95000000; c: loss from bp:114000000; d: gain until bp:100000000; e: loss from 80-90000000; n.d., not determined; NI, noninformative
marker; CR 1, core region 1; allelic imbalance around makers D10S173 and D10S190; CR 2, core region 2; allelic imbalance around markers
D10S541 and D10S1765.
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(Additional file 8). The origin of these brain-specific
aberrations in metastases could be explained by different
hypotheses [45]. The first one is that only few cells car-
ried these genetic alterations in the primary tumors, and
thus they could not be detected when the tumors were
analyzed in bulk. Subsequently, cells with these altera-
tions selectively metastasized to the brain and formed
the bulk of the metastases. Alternatively, these addi-
tional alterations might have occurred at the distant site
of metastasis, and therefore represent de novo mutations
that were not present in the primary tumors. The third
scenario is that only a small fraction of the primary
tumors contained these aberrations and that these
tumors are specifically prone to relapse in the brain.
Finally, another possibility is that several cells metasta-
size to the brain (for example, as a tumor-thrombus),
but only those with alterations at 10q and/or 7p are
able to survive in the brain environment, giving rise to
metastases. Recently, by massively parallel DNA sequen-
cing, Ding et al. [46] showed that metastases were
indeed significantly enriched for shared mutations,
which supports the last model.
Matched primary and metastatic tumor samples could
be investigated in four cases by microsatellite analysis.
Three cases showed identical aberration patterns, whereas
in the fourth case, the AI imbalance was larger (that is, in
the metastases, the distal marker was also affected by AI).
Furthermore, primary tumor samples from patients in
whom brain metastasis later developed showed a fre-
quency of AI at 10q that was almost as high as in the
brain metastases, but AI was rarely seen in primary tumors
without brain relapse or other distant metastases. These
results indicate that the loss of 10q does exist in a fraction
of primary tumors with a high risk of developing brain
metastases. The size of the aberration can expand in
metastases and thus become more detectable by, for
example, CGH. Because aberrations in 10q were not asso-
ciated with any clinical factor other than brain relapse, this
implies that loss of 10q is a specific marker of brain metas-
tasis and is thus needed for the outgrowth of the breast
tumor in the brain. However, this hypothesis must be vali-
dated in future studies, both functionally and on indepen-
dent larger cohorts of patients.
The AIs were concentrated around two core regions, the
first one around markers D10S1765 and D10S541 contain-
ing the PTEN locus, and the second around markers
D10S1236 and D10S190 at 10q26. The PTEN gene located
at 10q23.31 is a well-described tumor-suppressor gene,
also in breast cancer; PTEN functions as an important
tumor suppressor by negatively regulating the PI3K-
mediated cell-signaling pathway [47]. The present micro-
array analysis showed that PTEN is significantly downre-
gulated in brain metastases compared with nonmetastatic
primary tumors. Furthermore, mutation screening of the
PTEN gene in brain tumors showed that the frequency of
the mutation was much higher (15%) in primary breast
tumors (none to 5%) than previously described [48,49].
Several studies have shown that ERBB2/HER2 and the
basal subtype of breast cancer are the predominant
types of breast cancer that metastasize to the brain
Table 2 Frequencies and P values for AI at chromosome 10q in primary breast tumors and metastases
Brain metastases
(n = 21)
All primary tumors (n
= 77)a
Primary tumors without
relapse (n = 39)
Primary tumors with brain
relapse (n = 10)
Primary tumors with other
relapse (n = 17)
n % n % P valueb n % P valueb n % P valueb n % P valueb
PTEN (CR1)c 11 52.4 18 23.4 0.006 7 17.9 0.003 5 50.0 n.s. 2 11.8 0.006
CR2c 10 47.6 22 28.6 n.s. 11 28.2 n.s. 5 50.0 n.s. 3 17.6 n.s.
all AI 13 61.9 29 37.7 n.s. 13 33.3 0.055 5 50.0 n.s. 5 29.4 n.s.
normal 8 38.1 48 62.3 - 26 66.7 - 5 50.0 - 12 70.6 -
aRelapse pattern not recorded for 11 patients. bP values calculated with the Fisher Exact test (brain metastases versus other groups). cCR1 and CR2 are included
in all AI. AI, allelic imbalance; CR2, core region 2; allelic imbalance around markers D10S190 and D10S1236; n.s., not significant; PTEN (CR1), core region 1 allelic
imbalance around markers D10S1765 and D10S541.
Table 3 PTEN mutations in brain metastases




Exon3 Exon4 Exon5 Exon6 result
BrM-6 Wt g.del
[72586_72627]
wt nd c.[del1241_1284] AI Het. loss
BrM-7 Wt No product wt wt Allele 1: c.[del1241_1665] Allele 2: [del1524_1665; dup1196_1240,
950_1240con1196_1523]
AI Het. loss
BrM-8 wt nd c.389C >
A
nd nd Normal nd
het. Loss, heterozygous loss; nd, not determined; wt, wild type.
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[43,50,51]. To avoid misleading results by analyzing
unmatched samples, the primary tumor sample cohort
was matched for the main clinicopathologic characteris-
tics in our AI analysis. When we classified the primary
tumors as being ER/PR-positive, triple-negative, and
HER2-positive tumors, no association was found
between PTEN status (or loss of 10q) and breast cancer
subtype, indicating that loss of PTEN is an independent
predictor of brain metastases. In a recent publication,
the protein expression of PTEN was analyzed in 54
brain metastasis samples from breast cancer patients
[52]; no correlation was found between PTEN loss and
subtype in this study. Furthermore, a high concordance
rate (83%) of PTEN expression was found among the 12
matched pairs. The authors also investigated the role of
PTEN expression in primary breast cancer progression
by using in silico expression datasets with 855 patients
[52]. They showed that, in all patients, lower levels of
PTEN expression were associated with a poor prognosis
and shorter time to brain recurrence, irrespective of
hormone-receptor and HER2 status after 5 years. Also,
this analysis was independent of subtype. In addition,
we found, by using the same data set, a significant
downregulation of PTEN expression among primary
tumor patients with brain relapse compared with
patients with bone relapse, but not to the lung. This
finding is in line with the findings from Bos et al. [4,5],
who found a significant overlap of brain with lung-
relapse signature, but not with the bone signature,
which argues for the important role of environment
interaction in metastasis formation in different organs.
Interestingly, the two predominant genes derived from
this breast cancer study on brain metastases also play a
prominent role in the development and progression of pri-
mary brain tumors. The PTEN gene is one of the key
tumor-suppressor genes found in primary glioblastomas,
and it is often (15% to 40%) silenced through mutations
(reviewed in [21]). Interestingly, also in glioblastomas,
PTEN inactivation does not seem to be required for
tumor initiation, but its loss is a hallmark for progression
to highly malignant cancer [53]. Together with EGFR
amplification, the loss of PTEN is the most frequent
alteration observed in primary glioblastomas. Thus, these
two genes, which are both involved in the PI3K kinase
pathway, may play a key role in the growth of malignant
cells in the brain environment and therefore might be sui-
table targets for therapeutic intervention.
Conclusions
In conclusion, the present results show that brain metas-
tases in breast cancer often carry very complex genomic
aberration patterns. Nevertheless, certain target genes,
such as PTEN and EGFR, are predominantly affected and
might therefore play an important role in brain metastasis
formation. The genetic analyses of these genes might con-
tribute to defining a subgroup of breast cancer patients
who are at high risk of developing brain metastases. More-
over, increasing knowledge about the genetics of brain
metastasis with regard to therapeutic targets and pathways
may eventually lead to new antimetastatic strategies.
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